Cadila Healthcare Jumps Over 2% After Receiving EIR For Its Baddi Facility From USFDA

Cadila Healthcare on Monday informed the bourses that its formulations facility at Baddi has received an Establishment Inspection Report (EIR) from the USFDA.

The company also reported that Zydus Cadila has received final approval from the USFDA for Mirtazapine Orally Disintegrating Tablets USP of 15 mg, 30 mg and 45 mg.

Meanwhile, Cadila Healthcare on Tuesday was up by 2.5% at Rs 503 per share at 09:57 hours IST on BSE. The stock touched a high of Rs 510 and a low of Rs 500.80 in the morning hours.

The stock has delivered over 55% returns in a year’s time. It has outperformed BSE Sensex and BSE Healthcare over the same period.

Cadila Healthcare Limited is a well-known research-oriented, technology-driven pharmaceutical company focused on the research areas of biotechnology, formulations and Active Pharmaceutical Ingredients.

For Quick Trial – 8962000225 ✔ 
or mail us here:
or visit
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔ 
Give a Missed Call for Free Trial - 09699997717 ✔

Share on Google Plus Share on Pinterest

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.